Bioequivalence trial of extended-release ondansetron (RHB 102) vs Zofran

Trial Profile

Bioequivalence trial of extended-release ondansetron (RHB 102) vs Zofran

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2015

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics; Registrational
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 30 Apr 2014 RedHill Biopharma plans to submit a European marketing application for RHB-102 for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting in cancer patients in Q3 of 2014 based on the positive results from this study.
    • 07 Apr 2014 RedHill Biopharma expects to report results in July 2014.
    • 07 Apr 2014 Status changed from planning to recruiting, as reported in a RedHill Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top